Published in Gene Therapy Weekly, December 12th, 2002
The phase Ib clinical trials of TNFerade, principally designed to assess the safety of the product candidate, were conducted at four centers around the country and involved patients with a wide variety of cancers including cancer of the pancreas, breast, lung, head and neck, skin, colon, and rectum. TNFerade showed substantial activity against a broad range of tumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.